TetraLogic cuts 18 in wake of study failure; Mapi sets IPO terms;

@FierceBiotech: Amgen's Humira biosimilar nears FDA nod, but legal hurdles remain. Story | Follow @FierceBiotech

@JohnCFierce: So I'll be hanging out at #BIOCEO16 in NYC for a couple of days. Should be fun. | Follow @JohnCFierce

> Malvern, PA-based TetraLogic ($TLOG) has laid off 19 staffers, including its chief scientific officer, according to an SEC filing. The move leaves the biotech with 10 employees. TetraLogic reported just a few weeks ago that its drug birinipant had failed to hit the primary endpoint in a Phase II study for MDS. CSO G. Glenn Begley and Dr. Lesley Russell, the COO, have both been terminated in the shakeup. Filing

> Mapi Pharma has laid out the terms to an IPO, seeking $15 to $17 a share for 3.1 million shares. The offering is valued at up to $61 million. Story

> GlaxoSmithKline ($GSK) is working through feasibility studies to see whether its vaccine platform could be put to use against Zika virus, which is spreading in Latin America. More

> Animal drug developer Aratana Therapeutics ($PETX) filed for its first FDA approval, submitting a treatment for pain and inflammation among dogs with osteoarthritis. Item

Medical Device News

@FierceMedDev: Theranos flagged by CMS for serious problems at California lab: WSJ. Report | Follow @FierceMedDev

@EmilyWFierce: Big Pharma chalks up victory in Arizona Supreme Court over Rx safety warnings. FiercePharma article | Follow @EmilyWFierce

> J&J hints at 'bold steps' in device deals in 2016, details 5 device collaborations. More

> U.K. startup reels in $45M in JJDC-backed round to boost liquid biopsy ambitions. Article

Pharma News

@FiercePharma: India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat. Story | Follow @FiercePharma

@EricPFierce: #EMA suspends Hubei Hongyuan Pharmaceutical after Czech inspectors find dust-covered plant and equipment. Article | Follow @EricPFierce

@CarlyHFierce: Invokana market share has trended upward post EMPA-REG, $JNJ says. Thank you, $LLY. | Follow @CarlyHFierce

> U.K. cost watchdog nixes pricey biologics for moderate rheumatoid arthritis. Story

> Novo Nordisk rolls out long-awaited Tresiba, aiming for blockbuster U.S. market share. More

Pharma Manufacturing News

> Pfizer recalls three lots of top seller Lyrica after production issues. More

> India's Mankind Pharma says it will build a plant in New Jersey. Report

> Inspectors find big issues at API repackager in France. Story

> Teva retrieves amphetamines over impurity concerns. Article

> Sterile injectables manufacturer Sagent said to be shopping itself. More

Pharma Asia News

> Indian firms in a race to buy Nasdaq-listed Sagent, report says. Report

> India and France committed to restart trade talks stalled on GVK row. Story

> Japan's Ono Pharmaceutical gears up sales reps for Opdivo. Item

> China-based VC firm WuXi Healthcare makes coast-to-coast U.S. investments. More

> India's Biocon takes a hit from analysts, but Mazumdar-Shaw upbeat. Article

Drug Delivery News

> Startup Co-D aims to resuscitate failed BMS drug using polymeric micelle drug delivery. More

> UNC team delivers cancer drugs wrapped in exosomes to cut doses. Report

> Combining light-activated and chemical treatments, new nanoparticles are more effective against tumors. Story

> Endangered inhaled insulin player MannKind collaborates with mysterious 'entity' on R&D. Item

> Cancer-focused Ensysce Biosciences adds opioid prodrug to its pipeline via merger. Article

Suggested Articles

The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.

Johns Hopkins scientists found that misfolded alpha-synuclein protein can travel from the gut and drive Parkinson's disease.

The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.